ERBB2 and breast carcinoma: First‐line application of TDM‐1 was evaluated for advanced HER2‐positive breast cancer patients, wherein the phase 3 MARIANNE trial compared T‐DM1 plus pertuzumab and T‐DM1 monotherapy with trastuzumab plus taxane (control group).